These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 25833460)

  • 21. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.
    Desai AS; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Chen F; Gong J; Rizkala AR; Brahimi A; Claggett B; Finn PV; Hartley LH; Liu J; Lefkowitz M; Shi V; Zile MR; Solomon SD
    Eur Heart J; 2015 Aug; 36(30):1990-7. PubMed ID: 26022006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.
    Balmforth C; Simpson J; Shen L; Jhund PS; Lefkowitz M; Rizkala AR; Rouleau JL; Shi V; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    JACC Heart Fail; 2019 Jun; 7(6):457-465. PubMed ID: 31078482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.
    McMurray JJ
    Eur J Heart Fail; 2015 Mar; 17(3):242-7. PubMed ID: 25756942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact.
    Buggey J; Mentz RJ; DeVore AD; Velazquez EJ
    J Card Fail; 2015 Sep; 21(9):741-50. PubMed ID: 26209000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF.
    Simpson J; Jhund PS; Silva Cardoso J; Martinez F; Mosterd A; Ramires F; Rizkala AR; Senni M; Squire I; Gong J; Lefkowitz MP; Shi VC; Desai AS; Rouleau JL; Swedberg K; Zile MR; McMurray JJV; Packer M; Solomon SD;
    J Am Coll Cardiol; 2015 Nov; 66(19):2059-2071. PubMed ID: 26541915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effects of LCZ696 in Patients With Hypertension Compared With Angiotensin Receptor Blockers: A Meta-Analysis of Randomized Controlled Trials.
    Zhao Y; Yu H; Zhao X; Ma R; Li N; Yu J
    J Cardiovasc Pharmacol Ther; 2017 Sep; 22(5):447-457. PubMed ID: 28793821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
    Jhund PS; McMurray JJ
    Heart; 2016 Sep; 102(17):1342-7. PubMed ID: 27207980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
    Ansara AJ; Kolanczyk DM; Koehler JM
    J Clin Pharm Ther; 2016 Apr; 41(2):119-27. PubMed ID: 26992459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.
    Vardeny O; Miller R; Solomon SD
    JACC Heart Fail; 2014 Dec; 2(6):663-70. PubMed ID: 25306450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neprilysin inhibition in chronic kidney disease.
    Judge P; Haynes R; Landray MJ; Baigent C
    Nephrol Dial Transplant; 2015 May; 30(5):738-43. PubMed ID: 25140014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Role of Neprilysin Inhibitors in Cardiovascular Disease.
    Mills J; Vardeny O
    Curr Heart Fail Rep; 2015 Dec; 12(6):389-94. PubMed ID: 26466607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A novel agent in the treatment of heart failure with depressed systolic function].
    Duarte Vera YC; Cáceres Vinueza SV; Daher Nader JE; Lara Terán JF
    Arch Cardiol Mex; 2018; 88(4):287-297. PubMed ID: 29501368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sacubitril/Valsartan: The Newest Addition to the Toolbox for Guideline-Directed Medical Therapy of Heart Failure.
    Rodgers JE
    Am J Med; 2017 Jun; 130(6):635-639. PubMed ID: 28285069
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial.
    Seferovic JP; Claggett B; Seidelmann SB; Seely EW; Packer M; Zile MR; Rouleau JL; Swedberg K; Lefkowitz M; Shi VC; Desai AS; McMurray JJV; Solomon SD
    Lancet Diabetes Endocrinol; 2017 May; 5(5):333-340. PubMed ID: 28330649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The safety of sacubitril-valsartan for the treatment of chronic heart failure.
    Tyler JM; Teerlink JR
    Expert Opin Drug Saf; 2017 Feb; 16(2):257-263. PubMed ID: 28060547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neprilysin Inhibitors: Emerging Therapy for Heart Failure.
    Owens AT; Brozena S; Jessup M
    Annu Rev Med; 2017 Jan; 68():41-49. PubMed ID: 27686019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin receptor neprilysin inhibitor LCZ696: a novel targeted therapy for arterial hypertension?
    Katsi V; Skalis G; Pavlidis AN; Makris T; Nihoyannopoulos P; Tousoulis D; Kallikazaros I
    Eur Heart J Cardiovasc Pharmacother; 2015 Oct; 1(4):260-4. PubMed ID: 27532450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.
    Vilela-Martin JF
    Drug Des Devel Ther; 2016; 10():1627-39. PubMed ID: 27274196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
    King JB; Shah RU; Bress AP; Nelson RE; Bellows BK
    JACC Heart Fail; 2016 May; 4(5):392-402. PubMed ID: 27039128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.